Treatment and Testing Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China: A Retrospective Real-world Study (REHEARSAL)
| Registry | NCT06585501, acronym REHEARSAL |
|---|---|
| Status | Completed |
| Study type | Observational |
| Enrollment | 805 (Actual) |
| Sponsor | Daiichi Sankyo (Industry) |
| Conditions | Gastric Cancer, Gastroesophageal Junction Cancer |
| Interventions | No drug (Other) |
| Dates | start 2024-08-15, primary completion 2025-07-30, completion 2025-07-30, first posted 2024-09-05, last updated 2025-08-21 |
| Locations | 9 sites in China |
Related Papers Related Patents Related Grants Related Experts
All trials for Gastric Cancer All trials for Gastroesophageal Junction Cancer All trials of No drug
This study will be conducted to retrospectively evaluate the treatment patterns in first-line, second-line, and subsequent lines of therapy for HER2-positive Gastric Cancer/Gastroesophageal Junction Cancer (GC/GEJC) patients.
This is a multicenter, non-interventional, retrospective real-world study to analyze the treatment patterns for patients with GC/GEJC in the first-line, second-line, and subsequent lines of treatment. The study will also assess different HER2 sample types, testing methods, and HER2 re-biopsy situations. By evaluating the treatment and testing patterns in clinical practice, this study aims to provide evidence and recommendations for improving the strategies for the treatment and testing of HER2-positive GC/GEJC patients.
| Arm | Type | Interventions | Description |
|---|---|---|---|
| GC/GEJC | Other: No drug | Patients diagnosed with locally advanced unresectable or metastatic HER2-positive GC/GEJC |
Sex: All, ages: 18 Years to any
Inclusion criteria * Patients with pathologically diagnosed locally advanced unresectable or metastatic GC/GEJC (limited to those diagnosed since October 1, 2017) and initiating first-line treatment between January 1, 2018, and March 31, 2023 * Patients aged ≥ 18 years at the time of diagnosis with locally advanced unresectable or metastatic GC/GEJC; HER2-positive status2, determined by either tissue samples from the first biopsy or liquid biopsy samples (if a patient has both tissue and liquid biopsy samples, tissue samples will be the standard). Exclusion criteria * Patients with other primary malignant tumors * Patients enrolled in clinical trials and receiving active anti-cancer therapy after July.1, 2017 (excluding retrospective studies). * Patients with critical missing data in medical records or otherwise deemed for inclusion by the investigator
| Facility | City | Country | Status |
|---|---|---|---|
| Beijing Cancer Hospital | Beijing | China | |
| The First Affiliated Hospital of Fujian Medical University | Fuzhou | China | |
| Zhejiang Provincial People's Hospital | Hangzhou | China | |
| Harbin Medical University Cancer Hospital | Harbin | China | |
| Affiliated Cancer Hospital of Shandong First Medical University | Jinan | China | |
| Liaoning Cancer Hospital & Institute | Shenyang | China | |
| The First Hospital of China Medical University | Shenyang | China | |
| The First Affiliated Hospital of Soochow University | Suzhou | China | |
| Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology | Wuhan | China |